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Lorena V. Hernández-Peña,2 and Angel Ordóñez-Quiroz2
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Background: Several studies have reported
that leptin levels, the leptin/adiponectin (L/A)
ratio and carbohydrate antigen (CA) 15-3
are especially elevated in breast cancer pa-
tients with high body mass index (BMI). The
purpose of this study was to evaluate BMI,
leptin, L/A ratio and CA 15-3 all together as
reliable biomarkers for breast cancer. Meth-
ods: Serum levels of leptin, adiponectin and
CA 15-3, as well as anthropometric and bio-
chemical parameters were analysed in 88
female patients who participated in a mam-
mography study. Predictive values of BMI,
leptin, L/A ratio and CA 15-3 were deter-
mined with a 95% confidence interval. Re-
sults: Women were diagnosed with either
breast cancer (n = 40) or benign breast le-
sions (n = 48). Among anthropometric pa-
rameters, age (P ≤ 0.001), weight (P ≤
0.05) and waist circumference (P ≤ 0.02)
were higher in patients with breast can-
cer than in patients without this pathology.
The 75th percentile values for BMI, leptin,
L/A ratio and CA 15-3 were 29.24 kg/m2,
26.65 ng/ml, 2.37 and 18.45 IU, respec-
tively. The suggested odds ratio for breast
cancer patients with the values that were
above the 75th percentile of the tetrad was
6.7 (0.7505–60.0665 confidence interval).
Conclusion: When the four variables were
analysed together, a sensitivity of 83.3%,
specificity of 80%, positive predictive value
of 83.3% and negative predictive value of
80% were obtained. Results indicate that
using the 75th percentile set points for BMI,
leptin, L/A ratio and CA 15-3 together could
offer a reliable approach to determine which
women are at high risk for developing breast
cancer. J. Clin. Lab. Anal. 27:12–20,
2013. C© 2012 Wiley Periodicals, Inc.
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INTRODUCTION
In Mexico in 2006, 71.9% of women were either over-
weight or obese. Several epidemiological studies have
shown that obesity is a major risk factor for the devel-
opment of many types of cancer such as endometrial cells
(1), hepatocellular carcinoma (2), colon (3, 4) and breast
cancer (5) in postmenopausal women (5–8).
The relationship between obesity and breast cancer has
made these diseases a challenge for both Mexican women
and the healthcare system (9–11). In this regard, the in-
cidence of breast cancer has recently shown an increas-
ing trend. This was especially true in the State of Mexico,
where the prevalence of breast cancer was 7.63 per 100,000
women in 2007 (12), and by 2008, in the entire country of
Mexico, 13,700 new cases of breast cancer were reported.
By 2009, there were 4,854 breast cancer related deaths in
women aged 25 and older, which figures out to 13 deaths
per day from this disease.
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It is well known that there are several biomarkers asso-
ciated with increased risk of breast cancer, including high
levels of leptin and low levels of adiponectin, suggesting
that the leptin/adiponectin (L/A) ratio should be useful
in determining breast cancer risk (4–6, 13–28).
Several studies suggest that leptin, a proinflammatory
adipocytokine (29), may act as a growth factor, promoting
the development of breast tissue carcinogenesis. As lep-
tin levels are directly related to body mass index (BMI),
it is important to study leptin in breast cancer to iden-
tify the mechanism by which this hormone induces the
development of malignant cells. New therapeutic targets
could then be identified and directed against the action of
leptin in neoplastic cells. The obRb leptin receptor acti-
vates the JAK2/STAT3 (where JAK is janus kinase and
STAT is signal transducer and activator of transcription)
signalling pathway, which induces the phenomena of cel-
lular immortality, proliferation and invasion (12, 30).
A study by Sun Hee concluded that patients with breast
cancer who had elevated levels of leptin, but lacked ex-
pression of its receptor in biopsied tissue samples, showed
increased survival rates. This study also showed that there
is little correlation between the expression of leptin and
its receptor with variables such as histological grade of
the lesion (N and T status according to the American
Joint Committee on Cancer (AJCC), human epidermal
growth factor receptor 2 (HER-2), B-cell lymphoma 2
(bcl-2) and p53 expression. However, a significant corre-
lation was found between the expression of leptin and its
receptor and Ki-67 antigen expression, a finding that sup-
ports the idea of leptin being a carcinogenesis-inducing
factor (31). This study showed the relationship between
the oestrogen receptor (ER) and leptin and its receptors
in the development and progression of breast cancer.
In contrast to leptin, adiponectin decreases as BMI
increases and has the opposite effect of leptin in breast
cancer cells, inhibiting their growth and promoting their
apoptosis. The expression of the adiponectin receptor in
the neoplastic cells of breast tissue is extremely important
in regulating the effects of leptin in these cells (15,17,32).
In a study by Jarde, adiponectin was found to inhibit
MCF-7 cell growth and induce the expression of the
adiponectin receptors AdipoR1 and AdipoR2a as well
as decrease the expression of leptin and its receptors in
these neoplastic cells. This study demonstrated that both
hormones are antagonistic to the development of breast
cancer (33), which suggests that the L/A ratio could be
used as a biomarker for breast cancer.
Evidence suggests that the carbohydrate antigen (CA)
15-3 is found in high concentrations in women with
metastatic breast cancer that are independent of standard
prognostic factors. High levels of CA 15-3 have also been
associated with poor prognosis because this biomarker
is associated with micrometastases, or hidden metastases,
which are not detectable by conventional methods. This
tumour marker is both easy to measure and relatively in-
expensive. However, one of the disadvantages of CA 15-3
as a breast cancer biomarker is its low specificity (34). The
aim of this study was to evaluate whether the tetrad BMI,




This study was a cross-sectional prospective study
conducted at the Maternal-Perinatal Hospital “Mónica
Pretelini” (HMPMP), State of Mexico Health Institute
(ISEM), Toluca, Mexico, from January to October 2011.
Patients
Women were recruited from the imagenology service of
the HMPMP.
Inclusion criteria
Female patients participating in a mammography study
with an average age of 40–50 years were included in the
study.
Exclusion criteria
Patients undergoing hormonal therapy were excluded
from the study.
Sample calculation
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in
a bilateral contrast, 36 subjects per group were required
to detect an odds ratio (OR) of 5. A proportion of 0.3
positive cases were assumed in one of the groups. The
estimation of losses was 0.1 (7).
Anthropometric measures
We measured weight (kg), height (m; Seca, GmbH, Ger-
many) and waist circumference (cm) of all study partici-
pants. Women were classified by BMI as (a) normal weight
(BMI < 24.9 kg/m2), (b) overweight (24.9 kg/m2 < BMI
< 29.9 kg/m2), (c) obese (BMI > 30 kg/m2).
Laboratory
Blood samples (BD Vacutainer R©, Franklin Lakes, NJ)
were taken and centrifuged to separate serum from cel-
lular material. We measured circulating blood levels of
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glucose (mg/dl), cholesterol (mg/dl), triglycerides
(mg/dl) and uric acid (mg/dl) in all patients. By enzymatic
methods, we determined levels of low-density lipopro-
tein cholesterol (LDLC, mg/dl), high-density lipopro-
tein cholesterol (HDLC, mg/dl) (Ximola, Randox) and
haemoglobin (g/dl; Act diff, Beckman Coulter). All these
tests were conducted at the Medical Research Center
(CICMED), Autonomous University of the State of Mex-
ico (UAEMex) according to standardised protocols rec-
ommended by the International Federation of Clinical
Chemistry and Laboratory Medicine (IFCC).
Serum concentrations of adiponectin and leptin were
measured using an enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions
(GenWay Biotech. Inc.; Adiponectin reference 40-055-
200002 and Leptin reference 40-055-200004). CA 15-3 lev-
els were determined using an electrochemiluminescence
immunoassay (Modular Analytics E170, Roche).
Mammography
Mammograms (Hologic LORAD SeleniaTM) were per-
formed in the morning after completing a risk factor ques-
tionnaire.
Biopsy
Women were categorised according to the Breast Imag-
ing Reporting and Data System (BI-RADS) score and St
Gallen criteria. Biopsies were taken using the ultrasound-
guided (Voluson E8, GE Healthcare) tru-cut biopsy tech-
nique (Angiotech Pharmaceuticals, Inc., Canada).
Pathology
Haematoxylin and eosin (HE) staining was performed
on paraffin-embedded biopsied tissue sections. Immuno-
histochemical analysis of the cancer tissue was conducted
at the Pathology Service of the State Cancer Center
(COE), ISSEMYM. If the tissue samples were determined
to be positive for cancer, immunohistochemical analy-
sis (Ventana BenchMark, Ventana Medical Systems Inc.,
Tucson, AZ) was performed. Tissue sections (4 μm) were
formalin-fixed (fixation time 6–8 h), paraffin-embedded
and analysed for the presence of the ER (anti-ER, 1DS
clone), progesterone receptor (PR; anti-PgR, RBT22
clone) and HER-2/neu (c-erb-2 clone, her-2/neu).
Ethics
This study was approved by the ethics committees of the
HMPMP and the CICMED and was carried out accord-
ing to the ethical standards of the Helsinki Declaration of
1964. Informed consent was obtained from all patients.
Statistical Analysis
Statistical analysis was performed using SPSS 20.0
software. We used parametric or non-parametric tests as
required by the variable distribution. The correlation co-
efficients (r) were determined by Pearson and Spearman
tests for normal or skewed variables, respectively. Finally,
we performed the analysis with receiver operator charac-
teristic (ROC) and the area under the curve (AUC) anal-
yses for leptin levels, L/A ratio, CA 15-3 levels and BMI.
Predictive values were obtained using the Bayes theorem.
Ransohoff and Feinstein methods were used to calculate
sensitivity and specificity.
RESULTS
Of the 1,624 total patients who participated in the 2011
mammography study, 88 patients were included in the cur-
rent study and were classified into two groups according
to the diagnoses of breast cancer (n = 40) or benign breast
disease (n = 48).
Table 1 shows the recorded anthropometric and bio-
chemical values from patients in the study. Compared
to the control group, cancer patients showed statisti-
cally significant differences in age (P ≤ 0.001), weight
TABLE 1. Anthropometric and Laboratory Values
Cancer Control
(n = 40) (n = 48)
Variable mean ± SD mean ± SD P
BMI (kg/m2) 28.1 ± 3.8 25.4 ± 4.9 0.004
Leptin (ng/ml) 22.6 ± 15.2 18.5 ± 11.6 0.158
L/A ratio 1.99 ± 2.3 2.0 ± 2.1 0.814a
CA 15-3 (IU) 21.5 ± 16.7 13 ± 5.7 0.001a
Age (years) 54 ± 10.9 41.2 ± 12.9 0.000
Weight (kg) 68.6 ± 10.8 63.4 ± 12.7 0.042




94.3 ± 10 88.2 ± 12.5 0.017
Glucose (mg/dl) 94.9 ± 28.5 91.1 ± 23.35 0.514a
Cholesterol
(mg/dl)
194.4 ± 34.9 178.6 ± 43.5 0.067
Triglycerides
(mg/dl)
159.1 ± 72 165.7 ± 128.0 0.489a
HDLC (mg/dl) 44.5 ± 9.6 45.7 ± 10.2 0.565
LDLC (mg/dl) 125.2 ± 25.4 110.2 ± 36 0.029
Uric acid (mg/dl) 4.1 ± 1.1 3.9 ± 1.1 0.373
Haemoglobin
(g/dl)
15 ± 1.6 15 ± 1.6 0.832
Adiponectin
(μg/ml)
14.6 ± 6 13.5 ± 7.5 0.439
BMI, body mass index; CA 15-3, carbohydrate antigen 15-3; HDLC,
high-density lipoprotein cholesterol; LDLC, low-density lipoprotein
cholesterol; L/A, leptin/adiponectin ratio.
aMann–Whitney U-test.
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TABLE 2. Anthropometric and Laboratory Values Classified by BMI in the Cancer Group
Normal weight Overweight Obese
(n = 5), (n = 25), (n = 10),
Variable median (range) median (range) median (range) Pa Pb
BMI (kg/m2) 23 (22–23) 27.1 (25–29.8) 32.3 (30–37.5) 0.000 0.000
Leptin (ng/ml) 7.7 (2.1–40.2) 16.7 (2.9–41) 39.3 (14.2–62.7) 0.012 0.000
L/A ratio 0.6 (0.1 -6.59) 1.1 (0.24–3.9) 2.6 (0.96–13.58) 0.010c 0.005c
CA 15-3 (IU) 10.8 (8.5–12.2) 13.9 (6.1–92.8) 22.35 (13.7–44.6) 0.003c 0.050c
Age (years) 53 (36–88) 55 (34–74) 49.5 (38–65) 0.384 0.167
Weight (kg) 56 (49.2–70) 66 (52.6–87) 79.5 (69.8–100.5) 0.001 0.000
Height (m) 1.58 (1.48–1.75) 1.6 (1.45–1.71) 1.56 (1.49–1.64) 0.614 0.852
Waist circumference (cm) 84 (73–105) 92 (82–109) 101.5 (92–124) 0.043 0.004
Glucose (mg/dl) 83 (82–85.6) 92 (66–202) 89 (56–118) 0.495c 0.838c
Cholesterol (mg/dl) 181 (157–208.9) 184 (132–305) 198 (166–288) 0.128 0.269
Triglycerides (mg/dl) 103 (56–170.4) 141 (74 –333) 164.5 (100–309) 0.199 0.623
HDLC (mg/dl) 44.9 (38.5–65.1) 40.8 (30.9–63.3) 40.8 (33.9–55.4) 0.335 0.655
LDLC (mg/dl) 104 (102–143.6) 120 (84– 179.1) 132.5 (100–213) 0.161 0.062
Uric acid (mg/dl) 3.8 (2.5–4.5) 3.8 (1.7–6.3) 4.6 (3.8–6.2) 0.040 0.045
Haemoglobin (g/dl) 15.1 (11.1–15.3) 15.6 (9- 16.8) 14.8 (13.5–16.2) 0.331c 0.188c
Adiponectin (μg/ml) 19.7 (6.1–20.1) 13 (4.6–25.1) 13.9 (4.1–23.7) 0.953 0.921
BMI, body mass index; CA 15-3, carbohydrate antigen 15-3; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol;
L/A, leptin/adiponectin ratio.
aBetween normal weight and obesity.
bBetween overweight and obesity.
cMann–Whitney U-test.
(P ≤ 0.05), waist circumference (P ≤ 0.05), CA 15-3 lev-
els (P ≤ 0.001), BMI (P ≤ 0.001) and LDLC levels (P ≤
0.05). Breast cancer patients also showed increased levels
of leptin, adiponectin and the L/A ratio compared to the
control group, but this finding did not reach statistical
significance. Table 2 shows the intra-group comparisons
according to BMI in patients diagnosed with cancer.
Leptin levels and L/A ratios were found to be directly
related to BMI, although the correlation between L/A
ratio and BMI was less significant. CA 15-3 levels only
increased in relation to a higher BMI in cases of positive
cancer diagnoses (Figure 1).
We used the 75th percentile values to determine high
risk values for each of the biomarkers. These values were
29.24 kg/m2 for BMI, 26.65 ng/ml for leptin levels, 2.37
for the L/A ratio and 18.45 IU for CA 15-3 levels. Us-
ing these data, we calculated predictive values (sensitivity,
specificity, positive predictive value (PPV) and negative
predictive value (NPV) for each biomarker. The results
are as follows: 25%, 83.3%, 55.5% and 57.1% for BMI;
30.7%, 81.6%, 57.1% and 59.7% for leptin; 23.1%, 75.5%,
42.9% and 55.2% for L/A ratio and 41%, 87.7%, 72.7%
and 65.1% for CA 15-3. The predictive values increased
(66.7%, 80%, 80% and 66.7%) when we took BMI and CA
15-3 levels into account. When BMI and leptin were eval-
uated together, the specificity decreased to 30% (Figure 2).
To test the usefulness of the previous four biomarkers in
the diagnosis of breast cancer, the Bayes theorem was
used and a kappa value of 0.87 (Table 3) was obtained.
Fig. 1. Relationship between sensitivity and specificity and the predic-
tive power of biomarkers in breast cancer.
(A) BMI > 29.24 kg/m2, (B) leptin > 26.65 ng/ml, (C) L/A ratio >
2.37, (D) CA 15-3 > 18.45 IU, (E) BMI > 29.24 kg/m2 and leptin >
26.65 ng/ml, (F) BMI > 29.24 kg/m2 and CA 15-3 > 18.45 IU, (G)
BMI > 29.24 kg/m2, leptin > 26.65 ng/ml, L/A ratio > 2.37 and CA
15-3 > 18.45 IU. BMI, body mass index; CA 15-3, carbohydrate antigen
15-3; L/A, leptin/adiponectin ratio.
The suggested OR for breast cancer patients using the
values above the 75th percentile for the tetrad was 6.7
(0.75–60.06 CI).
While the absence of oestrogen and PR was not associ-
ated with the cut-off values of the biomarkers used, BMI
J. Clin. Lab. Anal.
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Fig. 2. Differences in tetrad biomarkers between breast cancer patients (cases; n = 40) and patients with benign breast disease (controls; n = 48).
(A) BMI, (B) leptin, (C) L/A ratio and (D) CA 15-3. BMI, body mass index; CA 15-3, carbohydrate antigen 15-3; L/A, leptin/adiponectin ratio.
TABLE 3. Predictive Values for the Tetrad (BMI, Leptin, L/A
Ratio and CA 15-3)
95% CI
Lower limit Higher limit
Disease prevalence 54.55% 24.56% 81.86%
Truly diagnosed patients 81.82% 47.75% 96.79%
Sensibility 83.33% 36.48% 99.12%
Specificity 80.00% 29.88% 98.95%
Positive predictive value 83.33% 36.48% 99.12%
Negative predictive value 80.00% 29.88% 98.95%
Positive probability ratio 4.17 0.70 24.94
Negative probability ratio 0.21 0.03 1.31
False negatives 16.67%
was associated with HER-2-positive cases. Moreover, CA
15-3 levels were correlated with advanced breast cancer
but not with the L/A ratio (Table 4). According to the
results of the ROC curves, the variables with the greatest
AUC were age and waist circumference, which correspond
to postmenopausal women and obesity, respectively
(Figure 3).
Given the data from Table 5, which shows an associa-
tion between BMI, leptin levels, the L/A ratio and CA 15-
3 levels with the immunohistochemical markers of breast
cancer patients, we have noted a significant correlation be-
tween serum leptin levels and HER-2 status (P < 0.001).
Surprisingly, tumours that were negative for HER-2
presented higher BMI levels than tumours expressing this
marker.
J. Clin. Lab. Anal.
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TABLE 4. Biomarkers and the Clinical Stage of Tumour Progression
Patients with BMI, median Leptin, median L/A ratio, CA 15-3,
Variable cancer, N (%) (range) (range) median (range) median (range)
Clinical stage (n = 31)
I 4 (12.9) 28 (26.8–30.7) 25.5 (9.1–43.4) 1.97 (0.57–4.5) 12.2 (10.5–20.5)
II 9 (29) 28 (23–33) 21.4 (4.8–41.1) 1.04 (0.51–2.76) 13.7 (8.2–44.6)
III 11 (35.4) 28 (22–37.5) 16.7 (2.1–62.7) 1.2 (0.1–13.6) 14.1 (8.5–92.8)
IV 7 (22.5) 25 (22.8–32.5) 13.7 (2.9–22.9) 0.97 (0.24–1.58) 13.6 (11.2–46.9)
Histopathological report (n = 40)
Infiltrating ductal carcinoma 31 (77.5) 26.9 (22–37.5) 18.3 (2.1–62.7) 1.1 (0.1–13.6) 13.7 (8.2–92.8)
Invasive lobular carcinoma 3 (7.5) 30 (26.9–32.1) 17.8 (14.2–33.6) 2.38 (1.22–2.58) 19 (14.1–29.1)
Mucinous carcinoma 1 (2.5) 37.3 54.2 4.88 22.7
Myofibroblastoma 1 (2.5) 29 19.6 0.82 6.1
Carcinoma in situ 4 (10) 28.6 (27.3–31.6) 18.3 (13.6–40.4) 1.2 (1.1–1.7) 20.2 (11.3–28.9)
Immunohistochemistry (n = 31)
ER+ 27 (87.1) 28 (22–37.5) 18.7 (2.1–62.7) 1.2 (0.1–13.6) 14.1 (8.2–92.8)
ER− 4 (12.9) 25 (22.8–28) 10.9 (2.9–22) 0.88 (0.2–1.1) 12.9 (11.2–32.7)
PR+ 25 (80.6) 28 (22–37.5) 21.4 (2.1–62.7) 1.4 (0.1–13.6) 13.9 (8.2–92.8)
PR− 6 (19.4) 25 (22.8–32.1) 13.9 (2.9–22) 0.96 (0.24–1.2) 13.86(11.2–46.9)
HER-2 positive 3 (9.6) 25 (25–25.8) 13.7 (2.9–14.5) 1 (0.24–1) 33.1 (13.6–46.9)
Triple negative 3 (9.6) 25(22.8–28) 15.3 (6.6–22) 0.88 (0.88–1.15) 12.2 (11.2–32.7)
ER+ PR+ 25 (80.6) 28 (22–37.5) 21.4 (2.1–62.7) 1.4 (0.1–13.6) 13.9 (8.2–92.8)
ER– PR– 4 (12.9) 25 (22.8–28) 10.95 (2.9–22) 0.88 (0.24–1.15) 12.9 (11.2–32.7)
CA 15-3, carbohydrate antigen 15-3; BMI, body mass index; PR, Progesterone receptor; ER, oestrogen receptor; HER-2, human epidermal growth
factor receptor 2; L/A, leptin/adiponectin ratio.
DISCUSSION
Obesity is associated with many types of cancer (4, 35,
36). Moreover, the increasing incidence of breast cancer,
increasing rates of obesity and the association between
them, has become a major challenge to maintaining the
health of Mexican women. One probable explanation for
this association resides in the overstimulation of the leptin
pathway.
First, with regard to the age of the patients younger
than 40 years (range 35–40), only 5 of 26 were diag-
nosed with cancer, of which 3 were overweight and 2 were
obese.
BMI is well established as a pro-cancerous factor
(37). However, BMI, leptin, adiponectin and ER are
also biomarkers associated with both obesity and breast
cancer (17, 23).
Clearly, elevated levels of leptin in obese patients are in-
volved in the development and progression of breast can-
cer (23) in postmenopausal women (21). This involvement
occurs not only through the direct action of leptin on neo-
plastic cells through the JAK2/STAT3 signalling pathway
mediated by interleukin-1 (IL-1; (38) but also through the
induced expression of other factors that are involved in the
carcinogenesis of breast tissue, such as oestrogen. Several
studies have reported that elevated serum levels of leptin
in breast cancer patients indicate a poorer prognosis and
lower survival rates. In our study, significant differences
were observed between the cohort of cancer patients who
were of normal weight and those who were overweight or
obese.
Adiponectin could have a role in the reduction of leptin
levels (32, 33). In our study, we did not find differences in
adiponectin levels between patients with cancer and those
without.
It has been postulated that the L/A ratio could be
more useful as a biomarker because both hormones in-
cluded in this formula are antagonistic in their final ef-
fect on tumourigenesis. Until now, this ratio has not
been widely used in prospective studies. In our study, the
L/A ratio increase was lower than that of leptin alone.
Therefore, this variable could indicate that a metabolic ad-
justment is taking place that has protective effects against
the increasing leptin levels. It could be possible to reduce
this ratio by correcting the patient’s diet, which would
modify the susceptibility to cancer through the inhibi-
tion of the leptin pathway. With regard to the CA 15-
3, it seems that obese patients are more susceptible to
increased levels of this marker regardless of the cancer
diagnosis.
Interestingly, in our work, it was observed that pa-
tients with lab values above the cut-off values for
the biomarkers included in the tetrad have differential
J. Clin. Lab. Anal.
18 Santillán-Benı́tez et al.
Fig. 3. ROC analysis in cases and controls of (A) leptin (AUC, 0.57 (95% CI, 0.64–0.71)) and waist circumference (AUC, 0.67 (95% CI, 0.6–0.82));
(B) BMI (AUC, 0.68 (95% CI, 0.56–0.79)), leptin (AUC, 0.59 (95% CI, 0.46–0.71)), L/A ratio (AUC, 0.53 (95% CI, 0.41–0.65)) and CA 15-3 (AUC,
0.71 (95% CI, 0.6–0.82)); (C) BMI (AUC, 0.67 (0.55–0.78)), leptin (AUC, 0.57 (95% CI, 0.45–0.7)), L/A ratio (AUC, 0.52 (95% CI, 0.4–0.65)),
CA 15-3 (AUC, 0.69 (95% CI, 0.58–0.81)), waist circumference (AUC, 0.67 (95% CI, 0.56–0.79)), age (AUC, 0.74 (95% CI (0.64–0.85)) and weight
(AUC, 0.62 (95% CI (0.5–0.74)). AUC, area under the curve; BMI, body mass index; CA 15-3, carbohydrate antigen 15-3; L/A, leptin/adiponectin
ratio; ROC, receiver operator characteristic.
expression of oestrogen and progesterone in their cancer
cells (ER+/PR+; (39)).
This study demonstrates the usefulness of using BMI,
leptin levels, the L/A ratio and CA 15-3 levels together
as biomarkers for breast cancer. Further prospective and
longitudinal studies should be conducted in order to
corroborate this conclusion. Using the biomarkers pro-
posed here would provide more information about the
J. Clin. Lab. Anal.
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TABLE 5. BMI, Leptin, L/A Ratio, CA 15-3 and Their Associ-




Variable N (%) BMI P Leptin P ratio P 15-3 P
Immunohistochemistry (n = 31)
ER+ 27 (86.2) 0.117 0.227 0.137a 0.476a
ER− 4 (13.8)
PR+ 25 (80.6) 0.209 0.014 0.190a 0.903a
PR− 6 (19.4)
HER-2 negative 28 (90.3) 0.001 0.197 0.229a 0.204a
HER-2 positive 3 (10.7)
ER+ PR+ 25 (80.6) 0.121 0.165 0.160a 0.562a
ER– PR– 4 (19.4)
aMann–Whitney U–test.
CA 15-3, carbohydrate antigen 15-3; BMI, body mass index; PR, Pro-
gesterone receptor; ER, oestrogen receptor; L/A, leptin/adiponectin
ratio.
association between obesity and breast cancer as well as
some benign conditions such as fibroadenomas and fibro-
cystic breast disease.
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